tldrdailynews.com logo

Bristol Myers' Next Multiple Myeloma Pill: Promising Results with Mezigdomide

1 min read
Source: Endpoints News
Bristol Myers' Next Multiple Myeloma Pill: Promising Results with Mezigdomide
Photo: Endpoints News
TL;DR

Bristol Myers Squibb's experimental pill, mezigdomide, has shown promising efficacy in a Phase II clinical trial for advanced multiple myeloma patients. The drug, classified as a "molecular glue," demonstrated a response rate of 41% and a median duration of response of 7.6 months. Patients did not experience cancer progression for a median of 4.4 months.

Topics:businesshealthcare#bristol-myers-squibb#clinical-trial#healthcare#mezigdomide#molecular-glue#multiple-myeloma
Share this article
  1. As Revlimid sales fall, Bristol Myers turns to its next multiple myeloma pill that's a molecular glue  Endpoints News
  2. Oral agent found to produce high response rate in patients with multiple myeloma when combined with steroid  Medical Xpress
  3. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma | NEJM  nejm.org
  4. BMS publishes 'modest' multiple myeloma survival data on heir to Revlimid, Pomalyst  FierceBiotech
  5. Mezigdomide Plus Dexamethasone Elicits Responses With Acceptable Safety in R/R Myeloma  OncLive
  6. View Full Coverage on Google News

Want the full story? Read the original reporting

Read on Endpoints News